Aptamer-Nanoparticle Enhances Paclitaxel Delivery
Author Information
Author(s): Yu Chenchen, Hu Yan, Duan Jinhong, Yuan Wei, Wang Chen, Xu Haiyan, Yang Xian-Da
Primary Institution: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Hypothesis
Can MUC1 aptamer-conjugated nanoparticles improve the delivery of paclitaxel to MUC1-positive cancer cells?
Conclusion
The study demonstrates that MUC1 aptamer-nanoparticle bioconjugates significantly enhance the delivery and cytotoxicity of paclitaxel to MUC1-positive cancer cells in vitro.
Supporting Evidence
- The MUC1 aptamer increased the uptake of nanoparticles into MCF-7 cells.
- PTX loaded Apt-NPs enhanced in vitro drug delivery and cytotoxicity to MUC1+ cancer cells.
- The aptamer-conjugated nanoparticles showed a sustained drug release profile.
Takeaway
Researchers created special nanoparticles that can deliver cancer medicine directly to cancer cells that have a specific marker called MUC1, making the treatment more effective.
Methodology
The study involved creating nanoparticles loaded with paclitaxel and conjugating them with MUC1 aptamers, followed by testing their effectiveness in MCF-7 breast cancer cells.
Limitations
The study was conducted in vitro, and further in vivo studies are needed to confirm the findings.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website